Information about Truqap (Capivasertib)
Truqap (Capivasertib) is currently undergoing clinical trials and has not yet received approval for widespread use. It is designed to target and inhibit AKT, a protein that plays a central role in the regulation of cell growth, survival, and metabolism. Dysregulation of the AKT pathway is common in many cancers, and by blocking this signaling, Capivasertib may reduce the proliferation of cancer cells and improve treatment outcomes for patients with specific types of cancer, such as breast cancer and other solid tumors.
Product Highlights
- Truqap is being studied for the treatment of advanced or metastatic breast cancer, particularly for cancers with alterations in the PIK3CA gene or other components of the PI3K/AKT/mTOR pathway.
- Capivasertib is also being explored for the treatment of other types of solid tumors, including ovarian, prostate, and lung cancers, that may harbor mutations in the AKT signaling pathway.
- Truqap is being investigated as part of combination therapy for patients whose cancers are resistant to standard treatments or who have progressed after initial therapies.
Key Ingredient
Key Benefits
- Capivasertib selectively targets and inhibits the AKT pathway, which is overactive in many cancers, offering a more precise treatment approach compared to conventional chemotherapy.
- It is being investigated in combination with other cancer therapies, potentially enhancing its effectiveness and overcoming resistance to other treatments.
- Truqap may offer new treatment options for cancers that are resistant to traditional therapies or that have progressed after initial treatments.
- Because it targets specific cancer cell pathways, Truqap may cause fewer side effects compared to traditional, non-targeted chemotherapy drugs.
Direction of Use
- The dosage of Truqap (Capivasertib) is determined by the results of clinical trials, and it will depend on the specific cancer being treated, the patient's individual response, and whether Capivasertib is being used alone or in combination with other treatments.
- Truqap is administered orally in tablet form, typically once or twice a day, depending on the treatment regimen prescribed by the oncologist.
- The dosing schedule may follow specific cycles, with breaks between treatment periods to allow the body to recover and monitor for side effects.
Safety Concerns
- Like other targeted therapies, Truqap may cause side effects, including nausea, diarrhea, fatigue, and liver toxicity. Close monitoring during treatment is necessary to manage these issues.
- Capivasertib may affect liver function, and patients may need regular blood tests to check liver enzymes and ensure there is no significant liver damage.
- As with other cancer treatments, Truqap may lower the body’s ability to fight infections, so patients should be monitored for signs of infection.
- AKT inhibitors have been associated with changes in blood sugar levels, so monitoring glucose levels may be required during treatment.
- Truqap should not be used during pregnancy as it may cause harm to the developing fetus. Women who are pregnant or planning to become pregnant should avoid Truqap.
Avoid Truqap (Capivasertib) If
- You are pregnant or planning to become pregnant as it may harm the fetus.
- You are breastfeeding as it is not known if Capivasertib passes into breast milk and could potentially harm a nursing infant.
- You have a history of severe liver disease or abnormal liver function, as Capivasertib may cause liver toxicity.
- You have an active infection or are at a high risk for infections, as Capivasertib can lower the body’s immune defenses.
- You have a history of high blood sugar (diabetes) or glucose imbalances, as Capivasertib can affect blood sugar levels.
- You have a known allergy to Capivasertib or any of its inactive ingredients.
